Status:

COMPLETED

A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders

Lead Sponsor:

Reneo Pharma Ltd

Conditions:

Fatty Acid Oxidation Disorder

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of the study is to collect information on disease characteristics from adult patients diagnosed with fatty acid oxidation disorders (FAOD).

Detailed Description

In this study there will be no drug intervention. The study will include a Baseline visit and a follow up visit scheduled at Month 4. At these visits medical history, safety assessments, concomitant m...

Eligibility Criteria

Inclusion

  • A genetically confirmed diagnosis of one of the following:
  • Carnitine palmitoyltransferase 2 deficiency
  • Very long-chain Acyl-CoA dehydrogenase deficiency
  • Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
  • Trifunctional protein deficiency
  • A stable treatment regimen for at least 30 days
  • Ambulatory and able to perform the study exercise test, using walking aids if necessary
  • Willing and able to personally sign and date an informed consent document indicating that the subject has been informed of all pertinent aspects of the study

Exclusion

  • Unstable or poorly controlled disease as determined by one or more of the following:
  • Presence of symptoms of acute rhabdomyolysis with clinically significant elevations in serum CK
  • Evidence of acute crisis from their underlying disease
  • Currently taking a PPAR agonist
  • Have motor abnormalities other than those related to the fatty acid oxidation disorder that could interfere with the study procedures, as determine by the investigator
  • Evidence of significant concomitant medical or psychiatric disease that in the opinion of the Investigator may interfere with the conduct or safety of this study
  • Pregnant or nursing females

Key Trial Info

Start Date :

January 15 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

May 4 2022

Estimated Enrollment :

61 Patients enrolled

Trial Details

Trial ID

NCT04482049

Start Date

January 15 2021

End Date

May 4 2022

Last Update

November 18 2023

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

Oregon Health & Science University (OHSU)

Portland, Oregon, United States, 97239

2

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15261

3

Vanderbuilt University Medical Center

Nashville, Tennessee, United States, 37232

4

Medizinische Universität Innsbruck

Innsbruck, Austria, A-6020